MYK-224 + verapamil

MYK-224 + verapamil refers to the co-administration of MYK-224, an investigational cardiac myosin inhibitor, and verapamil, a well-established calcium channel blocker. MYK-224 is being developed for the treatment of hypertrophic cardiomyopathy and acts by inhibiting excessive cardiac myosin activity, thereby reducing hypercontractility of the heart muscle. Verapamil is a small-molecule calcium channel blocker that reduces myocardial contractility and is commonly used for hypertension, angina, and certain arrhythmias. The combination is studied to assess potential pharmacokinetic interactions, as verapamil can influence the metabolism and plasma levels of co-administered drugs by inhibiting certain cytochrome P450 enzymes. No fixed-dose combination product exists; this entry describes their combined administration in clinical research settings, not a marketed formulation[1][3].